Nisin Z [137061-46-2]

Nisin Z has anti-inflammatory activity and reduces pro-inflammatory cytokine release by inhibiting activation of the ERK1/2 and p38 mitogen-activated protein kinase (MAPK) signaling pathways, attenuating lipopolysaccharide-induced mastitis through inhibition of the ERK1/2 and p38 mitogen-activated protein kinase signaling pathways.

Nisin Z (10 μg/mL, 24 h) promoted the detachment and differentiation of gingival fibroblasts.Nisin Z (25-75 μg/mL, 24 h) inhibited the adhesion of C. albicans to gingival cells. [2]
Nisin Z (500 and 1000 μg/mL, 24 hours) inhibited the formation of germ tubes in C. albicans. [3]
Nisin Z (100 μg/mL, 12 h) decreased LPS-induced secretion of pro-inflammatory cytokines (e.g., IL-6, TNF-α, IL-1β) in MCF10A cells Nisin Z (10-100 μg/mL, 12 h) inhibited LPS-induced activation of the ERK1/2 and p38 MAPK signaling pathways in MCF10A cells. [4]

Nisin Z (1, 5 and 10 mg/kg, intraperitoneal injection) helps to prevent pathological damage in LPS-induced mouse mastitis model. [4]

H2O: 8 mg/mL (2.4 mM), Sonication is recommended.

DMSO: 1 mg/mL (0.3 mM), Sonication is recommended.